| Outcome Measures: |
Primary: Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26, Severe hypoglycemia is defined as requiring third-party intervention. Documented symptomatic hypoglycaemia is defined as typical symptoms of hypoglycemia with an accompanying plasma glucose concentration \<=70 milligram (mg) per decilitre (dL) (\<=3.9 millimole per liter \[mmol/L\])., Up to Week 26|Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26, Week 26 | Secondary: Change from baseline in body weight at Week 26 and over time, Up to Week 26|Total daily insulin dose, basal insulin dose and bolus insulin dose at Week 26 and over time, Up to Week 26|HbA1c change from baseline in over time, Up to Week 26|Fasting plasma glucose (FPG) change from Baseline at Week 26 and over time, Up to Week 26|Proportion of subjects achieving a HbA1c <7.0% and < 6.5% at Week 26 and over time, Up to Week 26|Percentage of subjects achieving HbA1c <7.0% without weight gain after 26 weeks of treatment, Up to Week 26|Percentage of subjects achieving HbA1c <7.0% without severe or documented symptomatic hypoglycemia after 26 weeks of treatment, Up to Week 26|Percentage of subjects achieving HbA1c <7.0% without weight gain and without severe or documented hypoglycemia after 26 weeks of treatment, Up to Week 26|Number of subjects with non-serious adverse events (AE), serious adverse events (SAE), and AEs and SAEs leading to discontinuation, Up to Week 30|Incidence of hypoglycemic events, Up to Week 30|Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations, Up to Week 30
|
